207 related articles for article (PubMed ID: 33214550)
1. Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer.
Liu Y; Ji X; Kang N; Zhou J; Liang X; Li J; Han T; Zhao C; Yang T
Cell Death Dis; 2020 Nov; 11(11):993. PubMed ID: 33214550
[TBL] [Abstract][Full Text] [Related]
2. Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo.
Ji X; Han T; Kang N; Huang S; Liu Y
Life Sci; 2020 Nov; 260():118274. PubMed ID: 32827545
[TBL] [Abstract][Full Text] [Related]
3. Endothelial-Specific Molecule 1 Inhibition Lessens Productive Angiogenesis and Tumor Metastasis to Overcome Bevacizumab Resistance.
Kang N; Liang X; Fan B; Zhao C; Shen B; Ji X; Liu Y
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428773
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors.
Jiang X; Zhang QL; Liu TG; Zhao WP; Yang M; Wang LN; Sun WL; Pan L; Luo AP; Huang JC; Gu XH
Curr Pharm Des; 2019; 25(8):862-870. PubMed ID: 30848190
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
8. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
9. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells promote macrophage polarization toward M2b-like cells.
Kudlik G; Hegyi B; Czibula Á; Monostori É; Buday L; Uher F
Exp Cell Res; 2016 Oct; 348(1):36-45. PubMed ID: 27578361
[TBL] [Abstract][Full Text] [Related]
11. Preconditioning of bone marrow-derived mesenchymal stem cells highly strengthens their potential to promote IL-6-dependent M2b polarization.
Philipp D; Suhr L; Wahlers T; Choi YH; Paunel-Görgülü A
Stem Cell Res Ther; 2018 Oct; 9(1):286. PubMed ID: 30359316
[TBL] [Abstract][Full Text] [Related]
12. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5
Feng H; Liu K; Shen X; Liang J; Wang C; Qiu W; Cheng X; Zhao R
Cell Death Dis; 2020 Oct; 11(10):916. PubMed ID: 33099574
[TBL] [Abstract][Full Text] [Related]
14. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
15. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
16. Resolution of Spatial and Temporal Heterogeneity in Bevacizumab-Treated Breast Tumors by Eigenspectra Multispectral Optoacoustic Tomography.
Liapis E; Klemm U; Karlas A; Reber J; Ntziachristos V
Cancer Res; 2020 Dec; 80(23):5291-5304. PubMed ID: 32994204
[TBL] [Abstract][Full Text] [Related]
17. Whole Transcriptomic Analysis of Apigenin on TNFα Immuno-activated MDA-MB-231 Breast Cancer Cells.
Bauer D; Mazzio E; Soliman KFA
Cancer Genomics Proteomics; 2019; 16(6):421-431. PubMed ID: 31659097
[TBL] [Abstract][Full Text] [Related]
18. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
[TBL] [Abstract][Full Text] [Related]
19. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of TNFα in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.
Ji X; Peng Z; Li X; Yan Z; Yang Y; Qiao Z; Liu Y
Cancer Lett; 2017 Feb; 386():24-34. PubMed ID: 27832973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
